

14th October 2019

PYC to present at the annual meeting of the Oligonucleotide Therapeutics Society

Phylogica Limited, trading as **PYC Therapeutics**, (ASX: PYC) ('The Company' or 'PYC'), a drug development company, will attend the 15th annual meeting of the Oligonucleotide Therapeutics Society in Munich, Germany between 13 and 16 October 2019. PYC will use the conference to:

- i) present recent successful progress made in its lead drug program to treat Retinitis Pigmentosa, the leading cause of childhood blindness, to a number of industry participants; and
- ii) present information on the Company's unique delivery technology and lead drug program in poster format.

Copies of the posters to be presented by company representatives are available on the Company's new website at www.pyctx.com.

ENDS

For further information please contact:

Rohan Hockings, CEO
info@pyctx.com

About Retinitis Pigmentosa

Retinitis Pigmentosa 11 is a rare, severe genetic disease, affecting 4,000-8,000 people in the western world. A genetic mutation causes the retina of the eye to degrade with age, causing initial night-blindness, then tunnel vision, and finally, for many patients, complete blindness. There are currently no drugs for the genetic defect that causes our target indication of Retinitis Pigmentosa.

About PYC Therapeutics

Phylogica Limited trading as PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome 'the delivery challenge' and provide access for a wide range of potent and precise drug 'cargoes' to the 'undruggable genome' – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0992 | pyctx.com

Phylogica Limited trading as PYC Therapeutics

ACN 098 391 961